Zepbound reduces appetite, and attempting to eat normal pre-treatment portions can cause significant discomfort, nausea, and vomiting
Even modest weight loss (510%) can yield significant health improvements, so a plateau does not mean the medication isnt working
Affected individuals are typically characterised by lipoatrophic diabetes, insulin resistance and hepatic steatosis ( Agonists of the glucagon-like peptide-1 receptor (GLP-1R) deliver significant beneficial effects both in treating type 2 diabetes and obesity ( Reports of the effects of GLP-1R agonists in individuals with inherited lipodystrophies are currently limited to only 3 case studies, and these examine FPLD but not CGL patients ( Here we used a well validated Bscl2 -null (seipin knockout) mouse model of CGL type 2 (CGL2) to examine the effectiveness of a GLP-1R agonist, in treating lipoatrophic diabetes, hepatic steatosis and hyperphagia in CGL to inform the adoption of this class of drugs for individuals with lipodystrophy
Some patients reach their goal weight loss and stop titrating rather than advancing to maximum dose
This non-invasive treatment is designed to offer lasting results, helping you feel more confident and toned
